Search
Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
A The Kids researcher focused on ensuring kids are protected from infectious diseases will be named among WA’s most outstanding young scientists at the upcoming 2021 Young Tall Poppy Science Awards.
Dr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.
Human rhinovirus (HRV) species C (HRV-C) have been associated with frequent and severe acute lower respiratory infections and asthma in hospitalized children.
In the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...
The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
In Australia and many other developed countries, acute lower respiratory infection (ALRI) is one of the most common reasons for hospitalisation in young...
Acute lower respiratory infections (ALRI) are a major cause of hospitalisation in young children
Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of
Influenza is major cause of paediatric hospitalisation. Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008